Literature DB >> 29157745

Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT.

Shigetoshi Takaya1, Nobukatsu Sawamoto2, Tomohisa Okada3, Gosuke Okubo4, Sei Nishida5, Kaori Togashi4, Hidenao Fukuyama6, Ryosuke Takahashi7.   

Abstract

OBJECTIVE: We aimed to assess whether a combined analysis of dopamine transporter (DAT)- and perfusion-SPECT images (or either) could: (1) distinguish atypical parkinsonian syndromes (APS) from Lewy body diseases (LBD; majority Parkinson disease [PD]), and (2) differentiate among APS subgroups (progressive supranuclear palsy [PSP], corticobasal syndrome [CBS], and multiple system atrophy [MSA]).
METHODS: We recruited consecutive patients with neurodegenerative parkinsonian syndromes (LBD, n = 46; APS, n = 33). Individual [123I]FP-CIT- and [123I]iodoamphetamine-SPECT images were coregistered onto anatomical MRI segmented into brain regions. Striatal DAT activity and regional perfusion were extracted from each brain region for each patient and submitted to logistic regression analyses. Stepwise procedures were used to select predictors that should be included in the models to distinguish APS from LBD, and differentiate among the APS subgroups. Receiver-operating characteristic (ROC) analyses were performed to measure diagnostic power. Leave-one-out cross-validation (LOOCV) was performed to evaluate the diagnostic accuracy.
RESULTS: The model to discriminate APS from LBD showed that the area under the ROC curve (AUC) was 0.923, while the total diagnostic accuracy (TDA) was 86.1% in LOOCV. In the model to distinguish PSP, CBS, and MSA from LBD, the AUC/TDA values were 0.978/94.6%, 0.978/87.0%, and 0.880/80.3%, respectively. In the model to differentiate between CBS and MSA, MSA and PSP, and PSP and CBS, the AUC/TDA values were 0.967/91.3%, 0.920/88.0%, 0.875/77.8%, respectively.
CONCLUSION: An image-based automated classification using striatal DAT activity and regional perfusion patterns provided a good performance in the differential diagnosis of neurodegenerative parkinsonian syndromes without clinical information.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Parkinsonism; SPECT; [(123)I]FP-CIT; [(123)I]IMP

Mesh:

Substances:

Year:  2017        PMID: 29157745     DOI: 10.1016/j.parkreldis.2017.11.333

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  Multivariate radiomics models based on 18F-FDG hybrid PET/MRI for distinguishing between Parkinson's disease and multiple system atrophy.

Authors:  Xuehan Hu; Xun Sun; Fan Hu; Fang Liu; Weiwei Ruan; Tingfan Wu; Rui An; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-07       Impact factor: 9.236

2.  Arterial spin labeling imaging for the detection of cerebral blood flow asymmetry in patients with corticobasal syndrome.

Authors:  Tomohisa Yamaguchi; Masamichi Ikawa; Souichi Enomoto; Norimichi Shirafuji; Osamu Yamamura; Tetsuya Tsujikawa; Hidehiko Okazawa; Hirohiko Kimura; Yasunari Nakamoto; Tadanori Hamano
Journal:  Neuroradiology       Date:  2022-04-11       Impact factor: 2.995

3.  The Strengths and Obstacles in the Differential Diagnosis of Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA) Using Magnetic Resonance Imaging (MRI) and Perfusion Single Photon Emission Computed Tomography (SPECT).

Authors:  Piotr Alster; Michał Nieciecki; Bartosz Migda; Michał Kutyłowski; Natalia Madetko; Karolina Duszyńska-Wąs; Ingeborga Charzyńska; Dariusz Koziorowski; Leszek Królicki; Andrzej Friedman
Journal:  Diagnostics (Basel)       Date:  2022-02-02

Review 4.  Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus.

Authors:  Kazunari Ishii
Journal:  Jpn J Radiol       Date:  2019-09-23       Impact factor: 2.374

5.  Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.

Authors:  Florian Lipsmeier; Kirsten I Taylor; Timothy Kilchenmann; Detlef Wolf; Alf Scotland; Jens Schjodt-Eriksen; Wei-Yi Cheng; Ignacio Fernandez-Garcia; Juliane Siebourg-Polster; Liping Jin; Jay Soto; Lynne Verselis; Frank Boess; Martin Koller; Michael Grundman; Andreas U Monsch; Ronald B Postuma; Anirvan Ghosh; Thomas Kremer; Christian Czech; Christian Gossens; Michael Lindemann
Journal:  Mov Disord       Date:  2018-04-27       Impact factor: 10.338

Review 6.  Accumulation of Tau Protein, Metabolism and Perfusion-Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS).

Authors:  Piotr Alster; Natalia Katarzyna Madetko; Dariusz Mariusz Koziorowski; Leszek Królicki; Sławomir Budrewicz; Andrzej Friedman
Journal:  Front Neurol       Date:  2019-02-14       Impact factor: 4.003

7.  Thalamic and cerebellar hypoperfusion in single photon emission computed tomography may differentiate multiple system atrophy and progressive supranuclear palsy.

Authors:  Piotr Alster; Michał Nieciecki; Dariusz M Koziorowski; Andrzej Cacko; Ingeborga Charzyńska; Leszek Królicki; Andrzej Friedman
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 8.  Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.

Authors:  Usman Saeed; Anthony E Lang; Mario Masellis
Journal:  Front Neurol       Date:  2020-10-15       Impact factor: 4.003

9.  Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism.

Authors:  Minyoung Oh; Narae Lee; Chanwoo Kim; Hye Joo Son; Changhwan Sung; Seung Jun Oh; Sang Ju Lee; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

Review 10.  Neuroimaging in Lewy body dementia.

Authors:  Tayyabah Yousaf; George Dervenoulas; Polytimi-Eleni Valkimadi; Marios Politis
Journal:  J Neurol       Date:  2018-05-14       Impact factor: 4.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.